Design of peptide and polypeptide vaccines

Current Opinion in Biotechnology

Volumn 8, Issue 4, 1997, Pages 442-448

  Ben Yedidia, Tamar ^a   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DRUG CARRIER; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; LIPOSOME; MALARIA VACCINE; SYNTHETIC PEPTIDE; TUMOR ANTIGEN; VACCINE;

CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; PARASITE; PRIORITY JOURNAL; REVIEW; SCHISTOSOMIASIS; T LYMPHOCYTE; VACCINATION; VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030842457     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(97)80066-3     Document Type: Article

References (66)

1. Geerligs HJ, Weijer WJ, Welling GW, Welling WS: The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D. J Immunol Methods 1989, 124:95-102.
2. Newton SM, Joys TM, Anderson SA, Kennedy RC, Hovi ME, Stocker BA: Expression and immunogenicity of an 18-residue epitope of HIVI gp41 inserted in the flagellar protein of a Salmonella live vaccine. Res Microbiol 1995, 146:203-216.
3. Kalyan NK, Lee SG, Wilhelm J, Pisano MR, Hum WT, Hsiao CL, Davis AR, Eichberg JW, Robert GM, Hung PP: Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1. Vaccine 1994, 12:753-760.
4. Saikh KU, Tamura M, Kuwano K, Dai LC, West K, Ennis FA: Protective cross-reactive epitope on the nonstructural protein NS1 of influenza A virus. Viral Immunol 1993, 6:229-236.
5. Shirai M, Okada H, Nishioka M, Akatsuka T, Wychowski C, Houghten R, Pendleton CD, FeS, Berzofsky JA: An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 1994, 68:3334-3342.
6. Robertson MN, Buseyne F, Schwartz O, Riviere Y: Efficient antigen presentation to cytotoxic T lymphocytes by cells transduced with a retroviral vector expressing the HIV-1 Nef protein. AIDS Res Hum Retroviruses 1993, 9:1217-1223.
7. Connell N, Storer CK, Jacobs WR Jr: Old microbes with new faces: molecular biology and the design of new vaccines. Curr Opin Immunol 1992, 64:442-448.
8. Webster RG, Kawaoka Y, Taylor J, Weinberg R, Paoletti E: Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 1991, 9:303-308.
9. Hunt LA Brown DW, Robinson HL, Naeve CW, Webster RG: Retrovirus-expressed hemagglutinin protects against lethal influenza virus infections. J Virol 1988, 62:3009-3014.
10. Grene E, Mezule G, Borisova G, Pumpens P, Bentwich Z, Arnon R: Relationship between antigenicity and immunogenicity of chimeric Hepatitis B virus core particles carrying HIV-type epitopes. AIDS Res Hum Retroviruses 1997, 13:41-51.
11. Tam JP: Recent advances in multiple antigen peptides. J Immunol Methods 1996, 196:17-32. This paper describes recent progress in the use of MAPs, which are synthetic structures comprising multiple peptides polymerized on an oligolysine core. Such multivalent antigens induce a broad range of immune responses.
12. Toth GK, Varadi G, Nagy Z, Monostori E, Penke B, Hegedus Z, Ando I, Fazekas G, Kurucz I, Mak M et al.: Branched polypeptides as antigens for influenza virus hemagglutinin and T- cell receptor subunits. Pept Res 1993, 6:272-280.
13. Wang R, Charoenvit Y, Corradin G, Porrozzi R, Hunter RL, Glenn G, Alving CR, C hP, Hoffman SL: Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J Immunol 1995, 154:2784-2793. [Published erratum appears in J Immunol 1995, 155:1637.]
14. Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ et al.: A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996, 173:330-339.
15. Rose K, Zeng W, Brown LE, Jackson DC: A synthetic peptide-based polyoxime vaccine construct of high purity and activity. Mol Immunol 1995, 32:1031-1037.
16. Ben Ahmeida E, Gregoriadis G, Potter CW, Jennings R: Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. Vaccine 1993, 11:1302-1309.
17. Barr IG, Mitchell GF: ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol 1996, 74:8-25.
18. Hsu SC, Schadeck EB, Delmas A, Shaw M, Steward MW: Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunization. Vaccine 1996, 74:1159-1166.
19. McEwen J, Levi R, Horwitz RJ, Arnon R: Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice. Vaccine 1992, 10:405-411.
20. Levi R, Aboud PE, Leclerc C, Lowell GH, Arnon R: Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine 1995, 13:1353-1359.
21. Levi R, Arnon R: Effective protection of mice from viral challenge by an influenza synthetic recombinant vaccine with cross strain specifity. Chanock RM, Brown F, Ginsberg HS, Norrby ENY: CSHL Press; 1995:311-316.
22. Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, Ulmer JB, Liu MA: Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus [see comments]. Nat Med 1995, 1:583-587.
23. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL: DNA vaccines: a novel approach to immunization. Int J Immunopharmacol 1995, 17:79-83.
24. Liu MA: Overview of DNA vaccines. Ann NY Acad Sci 1995, 772:15-20.
25. Nomura M, Nakata Y, Inoue T, Uzawa A, Itamura S, Nerome K, Akashi M, Suzuki G: In vivo induction of cytotoxic T lymphocytes specific for a single epitope introduced into an unrelated molecule. J Immunol Methods 1996, 193:41-49.
26. Sarin PS, Mora CA, Naylor PH, Markham R, Schwartz D, Kahn J, Heseltine P, Gazzard B, Youle M, Rios A et al.: HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. Cell Mol Biol (Noisy-le-grand) 1995, 41:401-407.
27. Blazevic V, Ranki A, Krohn KJ: Helper and cytotoxic T cell responses of HIV type 1 -infected individuals to synthetic peptides of HIV type 1 Rev. AIDS Res Hum Retroviruses 1995, 11:1335-1342.
28. Fayolle C, Sebo P, Ladant D, Ullmann A, Leclerc C: In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J Immunol 1996, 156:4697-4706.
29. Lapham C, Golding B, Inman J, Blackburn R, Manischewitz J, Highet P, Golding H: Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T- cell responses in normal and in CD4+ cell-depleted BALB/c mice. J Virol 1996, 70:3084-3092.
30. Estaquier J, Gras MH, Boutillon C, Ameisen JC, Capron A, Tartar A, Auriault C: The mixotope: a combinatorial peptide library as a T cell and B cell immunogen. Eur J Immunol 1994, 24:2789-2795.
31. Gras MH, Ameisen JC, Boutillon C, Rouaix F, Bossus M, Deprez B, Neyrinck JL, Capron A, Tartar A: Synthetic vaccines and HIV-1 hypervariability: a 'mixotope' approach. Pept Res 1992, 5:211-216.
32. Partidos CD, Vohra P, Steward MW: Priming of measles virus-specific CTL responses after immunization with a CTL epitope linked to a fusogenic peptide. Virology 1996, 215:107-110.
33. Steward MW, Stanley CM, Obeid OE: A mimotope from a solid-phase peptide library induces a measles virus- neutralizing and protective antibody response. J Virol 1995, 69:7668-7673.
34. Obeid OE, Partidos CD, Steward MW: Identification of helper T cell antigenic sites in mice from the haemagglutinin glycoprotein of measles virus. J Gen Virol 1993, 74:2549-2557.
35. Obeid OE, Partidos CD, Steward MW: Analysis of the antigenic profile of measles virus haemagglutinin in mice and humans using overlapping synthetic peptides. Virus Res 1994, 32:69-84.
36. Obeid OE, Steward MW: The potential of immunization with synthetic peptides to overcome the immunosuppressive effect of maternal anti-measles virus antibodies in young mice. Immunology 1994, 82:16-21.
37. Steward MW, Partidos CD, D'Mello F, Howard CR: Specificity of antibodies reactive with hepatitis B surface antigen following immunization with synthetic peptides. Vaccine 1993, 11:1405-1414.
38. Shaw DM, Stanley CM, Partidos CD, Steward MW: Influence of the T-helper epitope on the titre and affinity of antibodies to B-cell epitopes after co-immunization. Mol Immunol 1993, 30:961-968.
39. Hsu SC, Shaw DM, Steward MW: The induction of respiratory syncytial virus-specific cytotoxic T-cell responses following immunization with a synthetic peptide containing a fusion peptide linked to a cytotoxic T lymphocyte epitope. Immunology 1995, 85:347-350.
40. Obeid OE, Partidos CD, Howard CR, Steward MW: Protection against morbillivirus-induced encephalitis by immunization with a rationally designed synthetic peptide vaccine containing B- and T-cell epitopes from the fusion protein of measles virus. J Virol 1995, 69:1420-1428.
41. Sedlik C, Sarraseca J, Rueda P, Leclerc C, Casal I: Immunogenicity of poliovirus B and T cell epitopes presented by hybrid porcine parvovirus particles. J Gen Virol 1995, 76:2361-2368.
42. Nussenzweig RS, Nussenzweig V: Development of sporozoite vaccine. Phil Trans R Soc Lond 1984, 307:117-128.
43. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heppner DG, Y uG, Hollingdale M, Slaoui M et al.: Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995, 171:576-585.
44. Patarroyo G, Franco L, Amador R, Morillo La, Rocha CA, Rogha M, Patarroyo ME: Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children age 1-14 years. Vaccine 1992, 10:175-178.
45. Ballou WR, Blood J, Chongsuphajaissidhi T, Gordon DM, Heppner DG, Kyle DE, Luxemburger C, Nosten F, Sadoff JC, Singhasivanon P et al.: Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study. Parasitology 1995, 107:25-36.
46. Fievet N, Maubert B, Cot M, Chougnet C, Dubois B, Bickii J, Migot F, Le Herson J, Frobert Y, Deloron P: Humoral and cellular immune responses to synthetic peptides from the Plasmodium falciparum blood-stage antigen, Pf155/RESA, in Cameroonian women. Clin Immunol Immunopathol 1995, 76:164-169.
47. Daly TM, Long CA: A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infect Immun 1993, 61:2462-2467.
48. Daly TM, Long CA: Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Infect Immun 1996, 64:2602-2608.
49. Snewin VA, Premawansa S, Kapilananda GM, Ratnayaka L, Udagama PV, Mattei DM, Khouri E, Del Giudice G, Peiris JS, Mendis KN et al.: Transmission blocking immunity in Plasmodium vivax malaria: antibodies raised against a peptide block parasite development in the mosquito vector. J Exp Med 1995, 181:357-362.
50. Bergquist NR: Controlling schistosomiasis by vaccination: a realistic opinion? Parasitol Today 1995, 11:191-194.
51. Boulanger D, Reid GD, Sturrock RF, Wolowczuk I, Balloul JM, Grezel D, Pierce RJ, Otieno M, Guerret S, Grimaud JA et al.: Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with Schistosoma mansoni. Parasite Immunol 1991, 13:473-490.
52. Kremer L, Riveau G, Baulard A, Capron A, Locht C: Neutralizing antibody responses elicited in mice immunized with recombinant bacillus Calmette-Guerin producing the Schistosoma mansoni glutathione S- transferase. J Immunol 1996, 156:4309-1437.
53. Soisson LA, Reid GD, Farah IO, Nyindo M, Strand M: Protective immunity in baboons vaccinated with a recombinant antigen or radiation-attenuated cercariae of Schistosoma mansoni is antibody-dependent J Immunol 1993, 151:4782-4789.
54. Reynolds SR, Shoemaker CB, Harn DA: T and B cell epitope mapping of Sm23, an integral membrane protein of Schistosoma mansoni. J Immunol 1992, 149:3995-4001.
55. Richter D, Reynolds SR, Harn DA: Candidate vaccine antigens that stimulate the cellular immune response of mice vaccinated with irradiated cercariae of Schistosoma mansoni. J Immunol 1993, 151:256-265.
56. Tarrab-Hazdai R, Levi-schaffer F, Brenner V, Horowitz S, Eshhar Z, Amon R: Protective monoclonal antibodies against Schistosoma mansoni Antigen isolation, characterization and suitability for active immunization. J Immunology 1985, 135:2272-2279.
57. Mendlovic F, Arnon R, Tarrab HR, Puri J: Genetic control of immune response to a purified Schistosoma mansoni antigen. II. Establishment and characterization of specific I-A and I-E restricted T-cell clones. Parasite Immunol 1989, 11:683-694.
58. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA: Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 1996, 156:3151-3158.
59. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ: Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 1996, 156:3911-3918.
60. Ossevoort MA, Feltkamp MC, Van VK Melief CJ, Kast WM: Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995, 18:86-94.
61. Linehan DC, Goedegebuure PS, Eberlein TJ: Vaccine therapy for cancer. Ann Surg Oncol 1996, 3:219-228.
62. Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT: New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 1996, 6:11-24.
63. Liu X, Sejbal J, Kotovych G, Koganty RR, Reddish MA, Jackson L, Gandhi SS, Mendonca AJ, Longenecker BM: Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides. Glycoconj J 1995, 12:607-617.
64. Avichezer D, Taylor-Papadimitriou J, Arnon R: A short synthetic peptide (DTRPAP) induces anti-mucin (MUC-1) antibody, which is reactive with human ovarian and breast cancer cells. Cancer Biochem Biophys 1997, in press.
65. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Gedde DT III, Stokke KT, Solheim BG, Egge TS, Soreide O, Thorsby E, Gaudernack G: Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 1996, 65:450-453. A pilot phase I/II study with a synthetic ras peptide used as a cancer vaccine. The principle is based on loading professional antigen presenting cells from peripheral blood with the peptide corresponding to the specific mutation in the tumor tissue of the patient.
66. Ciernik IF, Berzofsky JA, Carbone DP: Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 1996, 156:2369-2375.